Dysphonia induced by anti-angiogenic compounds-Reference-Cited by-同舟云学术

Dysphonia induced by anti-angiogenic compounds

Published:2013-12-18 Issue:4 Volume:32 Page:774-782
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Saavedra Erika,Hollebecque Antoine,Soria Jean-Charles,Hartl Dana M.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-013-0049-2.pdf

Reference77 articles.

1. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182–1186

2. Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20(21):4368–4380

3. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358(19):2039–2049

4. “Cancer: principles & practice of oncology: primer of the molecular biology of cancer.” [Online]. Available: http://solution.lww.com/cancermolecularbiology . [Accessed: 12-May-2013]

5. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (New York, NY) 219(4587):983–985

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identifying Medications Underlying Communication Atypicalities in Psychotic and Affective Disorders: A Pharmacovigilance Study Within the FDA Adverse Event Reporting System;Journal of Speech, Language, and Hearing Research;2023-09-13

2. The Clinical Impact of Vascular Endothelial Growth Factor/Receptor (VEGF/R) Inhibitors on Voice;Case Reports in Otolaryngology;2023-04-01

3. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system;Expert Opinion on Drug Safety;2021-12-31

4. Chemotherapy-related dysphonia: Similar and differentiating features of six cases;Int. Journal of Clinical Pharmacology and Therapeutics;2021-12-01

5. Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma;Journal of Gastroenterology and Hepatology;2021-11-17